CBPO’s Shandong Taibang subsidiary is 82.76% owned by CBPO (image). I believe that the rest is partially or wholly owned by the “Shandong Institute of biological products” (山东省生物制品研究所). The Institute’s website seems to say that their joint venture with CBPO has projected revenues of $900M annually (Renminbi) and projected income of $17.24M annually. This works out to an income margin of 1.91%. Gurufocus.com shows that CBPO’s net income margin for YE2013 was 26.85%. The discrepancy seems large.
(*EDIT 5/8/2015: Changed the net income margin number from 2014 to 2013.)

